Gambin was the first EMBL Australia group leader appointed to Single Molecule Science. His signature method combines cell-free protein expression with two-colour single-molecule coincidence and fluctuation spectroscopy, which sidesteps purification entirely: proteins are expressed, labelled and measured in lysate, an order of magnitude faster than conventional interaction assays. The biology is protein self-association and aggregation — alpha-synuclein in Parkinson's, cardiac and muscular disease proteins — where the size distribution of oligomers, not the mean, is the quantity of interest. Positioned against the established body of NV-ensemble quantum sensing work — DEER, nanoscale NMR and T1 relaxometry protocols operating at pT/sqrt(Hz) field sensitivity — the conceptual overlap with quantum biosensing is the insistence on distributions over averages, and his aggregation systems (paramagnetic-species-generating, redox-active amyloid) are a plausible target for T1-relaxometry-based NV detection at pT/sqrt(Hz) in the near term.

Kaminski's Laser Analytics Group develops laser-based super-resolution and fluorescence-lifetime imaging methods (STED, SIM, dSTORM, FLIM) and applies them, with long-time collaborator Gabriele Kaminski Schierle, to visualise amyloid protein aggregation in live cells and organisms as a route to understanding neurodegenerative disease; the group also directs the EPSRC Centre for Doctoral Training in Sensor Technologies.

Kaminski Schierle heads the Molecular Neuroscience Group, applying super-resolution and functional fluorescence imaging (developed with Clemens Kaminski) to gain molecular-level understanding of protein misfolding in Alzheimer's, Parkinson's and Huntington's disease models, including live-cell and whole-organism (C. elegans) imaging of amyloid aggregation.